Adaptimmune Therapeutics plc (ADAP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Adrian G. Rawcliffe | CEO & Director | 1.04M | -- | 1972 |
| Mr. William C. A. Bertrand Jr., Esq., J.D. | COO & Chief Compliance Officer | 703.1k | -- | 1965 |
| Ms. Cintia Piccina Pharm.D. | Chief Commercial Officer | 510.51k | -- | 1973 |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder | 677.4k | -- | 1967 |
| Ms. Joanna Brewer Ph.D. | Chief Scientific Officer | -- | -- | 1976 |
| Dr. Juli P. Miller Ph.D. | VP of Corporate Affairs & Investor Relations | -- | -- | -- |
| Ms. Kerry Sharp | Senior VP & General Counsel | -- | -- | -- |
| Ms. Dana Lynch | Senior Director of Corporate Communications | -- | -- | -- |
| Mr. John Lunger | Chief Patient Supply Officer | 645.91k | 148.2k | 1969 |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer | 676.19k | 65.02k | 1963 |
Adaptimmune Therapeutics plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 506
Description
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Corporate Governance
Upcoming Events
August 11, 2025 at 8:00 PM UTC - August 16, 2025 at 8:00 PM UTC
Adaptimmune Therapeutics plc Earnings Date